Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ITGB3-pulsed dendritic cell vaccine
- Development stage
- Preclinical
- Lead developer
- University of Michigan
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Parenteral
01
Overview
ITGB3-pulsed dendritic cell vaccine (ITGB3-DC) is an experimental cancer vaccine consisting of dendritic cells loaded with integrin beta-3 (ITGB3) antigens. Developed at the University of Michigan, this cell-based immunotherapy is designed to stimulate a specific immune response against ITGB3-expressing tumor cells, with a particular focus on targeting melanoma cancer stem cells (CSCs). Preclinical studies in mouse melanoma models have shown that ITGB3-DC can significantly inhibit tumor growth, especially when used in combination with other integrin-targeted vaccines (like ITGB1-DC) or immune checkpoint inhibitors such as anti-PD-L1.
- Other names
- integrin beta 3-pulsed dendritic cell vaccineITGB3-targeted DC vaccineITGB-3-targeted DC vaccineITGB 3-targeted DC vaccine
02
Targets
ITGB3 (Integrin beta-3)
Beyond the preview
Go deeper on ITGB3-pulsed dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITGB3-pulsed dendritic cell vaccine.